Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jul 4;6:28993. doi: 10.1038/srep28993

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016, Macmillan Publishers Limited

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

The effects of intravitreal injections of miR-200b regulators on mild (A–F) and severe (G–L) vascular lesions. (A–C,G–I) Fundus fluorescein angiograms before intravitreal injections. (D–F,J–L) Fluorescein angiograms obtained 1 week after injections. (A,D,G,J) Vascular lesions in eyes developing mild (A,D, arrows) and severe (G,J) fluorescein leak persisted before and after injection of scrambled miRNA. (B,E,H,K) miR-200b mimic inhibited vascular leak in established mild vascular lesions (arrows, B,E) but had little effects on established severe lesions (H,K). (C,F,I,L) anti-miR-200b promoted vascular leak from established mild vascular lesions (arrows, C,F) but had little effects on established severe lesions (I,L).